Read here for highlights on Royalty Pharma's strategic updates, share repurchase program, and dividend increase with ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Scotiabank analyst Greg Harrison maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today and set a price target of $48.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback